Panel Presentation: Accelerating precision oncology with matched FFPE and plasma biospecimens characterized using Discovery's SpecimenSeq™ NGS Service and QIAGEN's QIAseq Multimodal Panels

Bridging a deep understanding of molecular profiles with clinical information is critical to developing innovative precision medicine tools in oncology. Discovery’s recently launched SpecimenSeq product line makes this challenge easier for targeted oncology and liquid biopsy developers by delivering access to ethically collected biospecimen sets that are annotated with genomic and clinical characteristics. Join this webinar to learn how Discovery’s SpecimenSeq NGS Service and QIAGEN Multimodal Panels can help you advance precision oncology programs by:

• Efficiently verifying the presence of biomarker targets in study populations of interest

• Building study cohorts with confirmed driver mutations and other clinically relevant genomic variants across FFPE and matched plasma samples

• Accelerating timelines and reducing the cost of studies designed to:

o Identify responders versus non-responders

o Evaluate efficacy

o Discover and validate biomarker signatures for new liquid biopsy and other diagnostic tests as well as targeted therapies

Learning Objectives:

1. Efficient verification of the presence of biomarker targets in study populations of interest 

2. Build study cohorts with confirmed driver mutations and other clinically relevant genomic variants across FFPE and matched plasma samples 

3. Accelerate timelines and reduce cost of studies